alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of General Electric Company (the
"Company") on Form 10-Q for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Richard
Falk, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.
1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.



                                            /s/  RICHARD FALK
                                            ---------------------------------
                                                 Richard Falk
                                                 Chief Executive Officer
                                                 Feb 18, 2003
```

[Federal Register Volume 81, Number 151 (Friday, August 5, 2016)]
[Notices]
[Page 51880]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18661]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-9028-4]

Environmental Impact Statements; Notice of Availability

    Responsible Agency: Office of Federal Activities, General 
Information (202) 564-7146 or http://www.epa.gov/nepa.

Weekly receipt of Environmental Impact Statements (EISs)
Filed 07/25/2016 Through 07/29/2016
Pursuant to 40 CFR 1506.9.

Notice

    Section 309(a) of the Clean Air Act requires that EPA make public 
its comments on EISs issued by other Federal agencies. EPA's comment 
letters on EISs are available at: http://www.epa.gov/compliance/nepa/eisdata.html.
EIS No. 20160177, Draft Supplement, FHWA, VA, Hampton Roads Crossing 
Study, Comment Period Ends: 09/19/2016, Contact: Edward Sundra 804-775-
3357
EIS No. 20160178, Final, BLM, CO, Previously Issued Oil and Gas Leases 
in the White River National Forest, Review Period Ends: 09/06/2016, 
Contact: Gregory Larson 970-876-9000
EIS No. 20160179, Final, AFS, MT, Lower Yaak, OBrien, Sheep Project, 
Review Period Ends: 09/06/2016, Contact: Miles Friend 406-295-4693
EIS No. 20160180, Final, FERC, TX, Golden Pass LNG Export Project, 
Review Period Ends: 09/06/2016, Contact: Eric Howard 202-502-6263
EIS No. 20160181, Final, FERC, OH, Rover Pipeline, Panhandle Backhaul, 
and Trunkline Backhaul Projects, Review Period Ends: 09/06/2016, 
Contact: Kevin Bowman 202-502-6287
EIS No. 20160182, Final, BLM, CA, West of Devers Upgrade Project, 
Review Period Ends: 09/06/2016, Contact: Frank McMenimen 760-833-7150

    Dated: August 2, 2016.
Karin Leff,
Acting Director, NEPA Compliance Division, Office of Federal 
Activities.
[FR Doc. 2016-18661 Filed 8-4-16; 8:45 am]
BILLING CODE 6560-50-P
```
II

104TH CONGRESS

1ST SESSION S. 468

To extend the deadline under the Federal Power Act applicable to the

construction of a hydroelectric project in Ohio, and for other purposes.

IN THE SENATE OF THE UNITED STATES

FEBRUARY 23 (legislative day, FEBRUARY 22), 1995

Mr. GLENN (for himself and Mr. DEWINE) introduced the following bill; which

was read twice and referred to the Committee on Energy and Natural

Resources

A BILL

To extend the deadline under the Federal Power Act applicable to the construction of a hydroelectric project in Ohio,

and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. EXTENSION OF DEADLINE.

4 (a) IN GENERAL.—Notwithstanding the time period

5 specified in section 13 of the Federal Power Act (16

6 U.S.C. 806) that would otherwise apply to the Federal En7 ergy Regulatory Commission project numbered 9423, the

8 Commission may, at the request of the licensee for the

9 project, in accordance with the good faith, due diligence,
2

•S 468 IS

1 and public interest requirements of that section and the

2 Commission’s procedures under that section, extend the

3 time period during which the licensee is required to com4 mence the construction of the project, under the extension

5 described in subsection (b), for not more than 3 consecu6 tive 2-year periods.

7 (b) EFFECTIVE DATE.—This section shall take effect

8 on the date of the expiration of the extension of the period

9 required for commencement of construction of the project

10 described in subsection (a) that the Commission issued,

11 prior to the date of enactment of this Act, under section

12 13 of the Federal Power Act (16 U.S.C. 806).

Æ
[Federal Register Volume 89, Number 26 (Wednesday, February 7, 2024)]
[Notices]
[Pages 8436-8437]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02434]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the cooperative agreement applications, the disclosure 
of which would constitute a clearly unwarranted invasion of personal 
privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation 
Cooperative Agreement (U01 Clinical Trial Required); NIAID SBIR 
Phase II Clinical Trial Implementation Cooperative Agreement (U44 
Clinical Trial Required); Clinical Trial Planning Grants (R34 
Clinical Trials)
    Date: February 29, 2024.
    Time: 9:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane Rockville, MD 20892 
(Video Assisted Meeting).
    Contact Person: Annie Walker-Abbey, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, MSC 9834, 
Rockville, MD 20852, 240-627-3390, <a href="/cdn-cgi/l/email-protection#dabbbbb8b8bfa39ab4b3bbb3bef4b4b3b2f4bdb5ac"><span class="__cf_email__" data-cfemail="bfdededddddac6ffd1d6ded6db91d1d6d791d8d0c9">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)


[[Page 8437]]


    Dated: February 1, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02434 Filed 2-6-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<PAGE>
                                                                   EXHIBIT 23.3


                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants to BayCorp Holdings, Ltd. (the "Company"), we
hereby consent to the inclusion of our report dated February 10, 2003 (except
for the matters discussed in Note 8 to the Company's financial statements as to
which the date is March 24, 2003) in the Company's Annual Report on Form 10-K/A
for the fiscal year ended December 31, 2002 and to the incorporation by
reference of our report in the company's previously filed (i) Registration
Statement on Form S-3 (File No. 333-24281), (ii) Registration Statement on Form
S-8 (File No. 333-24269), (iii) Registration Statement on Form S-8 (File No.
333-42016), and (iv) Registration Statement on Form S-8 (File No. 333-71976).



/s/ VITALE, CATURANO & COMPANY P.C.



Boston, Massachusetts
June 6, 2003
Exhibit 23.1

Independent Auditors' Consent

The
Board of Directors and Stockholders
ICG Communications, Inc.:

We
consent to the incorporation by reference in the registration statement (No. 333-104237) on Form S-8 of ICG Communications, Inc. and subsidiaries of our
report dated March 31, 2004, with respect to the consolidated balance sheets of ICG Communications, Inc. and subsidiaries as of December 31, 2002 and 2003, and the related
consolidated statements of operations, stockholders' equity (deficit), and cash flows for the year ended December 31, 2001, the period January 1, 2002 to October 11, 2002
(Predecessor Company), the period October 12, 2002 to December 31, 2002 (Reorganized Company), and the year ended December 31, 2003, and all related financial statement schedules,
which reports appear in the December 31, 2003, annual report on Form 10-K of ICG Communications, Inc. and subsidiaries.

Our
report refers to a change in accounting related to adoption of Statement of Financial Accounting Standard No. 145,Rescission of FASB Statements No. 4, 44,
and 64, Amendment of FASB Statement No. 13,and Technical Corrections, effective October 11, 2002, and Statement
of Financial Accounting Standard No. 143,Accounting for Asset Retirement Obligations,effective January 1, 2003.

Our
report contains an explanatory paragraph that states that on October 10, 2002, the Company emerged from bankruptcy. The consolidated financial statements of the Reorganized Company reflect
assets at reorganization value and liabilities at fair value under fresh-start reporting as of October 11, 2002. As a result, the financial statements of the Reorganized Company are presented
on a different basis than those prior to the reorganization and, therefore, are not comparable in all material respects.

Our
report contains an explanatory paragraph that states that the Company's recurring losses from operations and net capital deficiency raise substantial doubt about the entity's ability
to continue as a going concern.

KPMG
LLP
Denver, Colorado
April 1, 2004

---

QuickLinks
**Exhibit 32.2**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THESARBANES-OXLEY ACT OF 2002**

 

The undersigned, the Chief Financial Officer of Gladstone CapitalCorporation (the “Company”), hereby certifies on the date hereof, pursuant to18 U.S.C. §1350(a), as adopted pursuant to Section 906 of TheSarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for thequarter ended June 30, 2009 (“Form 10-Q”), filed concurrentlyherewith by the Company, fully complies with the requirements of Section 13(a) orSection 15(d) of the Securities Exchange Act of 1934, as amended, andthat the information contained in the Form 10-Q fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 

Dated: August 3, 2009

 

 
| /s/ Gresford Gray       |   |
|-------------------------|--------|
| Gresford Gray           |   |
| Chief Financial Officer |   |

 

----
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                     National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; HIV Comorbidities.                

*Date:*                     March 25, 2024.                

*Time:*                     11:30 a.m. to 5:00 p.m.                

*Agenda:*                     To review and evaluate grant applications.                

*Place:*                     National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                

*Contact Person:*                     Elena Sanovich, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7351, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-594-8886,                     *sanoviche@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: January 25, 2024.

Miguelina Perez, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-01847 Filed 1-30-24; 8:45 am]

BILLING CODE 4140-01-P
<PAGE>
                                                                    EXHIBIT 3.6


                           CERTIFICATE OF AMENDMENT OF
                         CERTIFICATE OF DETERMINATION OF

                  SERIES A JUNIOR PARTICIPATING PREFERRED STOCK

                                       OF

                               ARADIGM CORPORATION


        The undersigned certify that:

        1. They are the President and Chief Executive Officer, and Acting Chief
Financial Officer, respectively, of Aradigm Corporation, a California
corporation (the "Corporation").

        2. Section 1 of the Certificate of Determination of Series A Junior
Participating Preferred Stock is amended to read in full as follows:

                "SECTION 1. DESIGNATION AND AMOUNT. One Million (1,000,000)
        shares of Preferred Stock, without par value, are designated "Series A
        Junior Participating Preferred Stock" with the rights, preferences,
        privileges and restrictions specified herein (the "Junior Preferred
        Stock"). Such number of shares may be increased or decreased by
        resolution of the Board of Directors; provided, that no decrease shall
        reduce the number of shares of Junior Preferred Stock to a number less
        than the number of shares then outstanding plus the number of shares
        reserved for issuance upon the exercise of outstanding options, rights
        or warrants or upon the conversion of any outstanding securities issued
        by the Corporation convertible into Junior Preferred Stock."

        3. The foregoing amendment of the Certificate of Determination of
Preferences of Series A Junior Participating Preferred Stock has been duly
approved by the Board of Directors pursuant to authority given by the
Corporation's Amended and Restated Articles of Incorporation.

        We further declare under penalty of perjury under the laws of the State
of California that the matters set forth in this certificate are true and
correct of our own knowledge.



Date: February 8, 2002


                                    /s/ Richard P. Thompson
                                    --------------------------------------------
                                    RICHARD P. THOMPSON
                                    President and Chief Executive Officer



                                    /s/ Michael Molkentin
                                    --------------------------------------------
                                    MICHAEL MOLKENTIN
                                    Acting Chief Financial Officer
#### Ex parte Alvaro ALCORTA.

No. 29628.

Court of Criminal Appeals of Texas.

March 5, 1958.

Fred A. Semaan, San Antonio, for appellant.

Hubert W. Green, Jr., Dist. Atty., Richard J. Woods, Asst. Dist. Atty., San Antonio, and Leon B. Douglas, State’s Atty., Austin, for the State.

BELCHER, Commissioner.

This is an appeal from an order denying application for bail, appellant being under indictment for the murder of his wife, a prior conviction with the death penalty assessed having been affirmed by this court in Alcorta v. State, Tex.Cr.App., 294 S.W.2d 112. But said conviction was thereafter set aside under the decision of the Supreme Court of the United States in Alcorta v. State of Texas, 355 U.S. 28, 78 S.Ct. 103, 2 L.Ed.2d 9, and remanded to the trial court in Alcorta v. State, Tex.Cr.App., 308 S.W.2d 519.

In cases of this kind we refrain from any discussion or comment upon the evidence.

We have considered all the facts and circumstances in evidence in the light of the decision of the Supreme Court of the United States, and we are unable to find that the trial judge abused his discretion in reaching the conclusion that this is not a bailable case.

The judgment is affirmed.

Opinion approved by the Court.
Footnote 7 cite – copied from EIA web page:

http://www.eia.gov/tools/faqs/faq.cfm?id=77&t=3

Frequently Asked Questions

How much of U.S. carbon dioxide emissions 

are associated with electricity generation?

Total U.S. energy-related emissions of carbon dioxide (CO2) by the electric power sector in 2012 

were 2,039 million metric tons, or about 39% of total U.S. energy-related CO2 emissions.

CO2 emissions from U.S. electricity generation by source, 20121

Source Million Metric Tons Share of Total

Coal 1,514 74%

Natural gas 494 24%

Petroleum 19 1%

Other212 1%

Total 2,039

1Preliminary 2012 data.

2Miscellaneous wastes and from geothermal power generation.

Learn more:

Monthly Energy Review, Tables 12.1 and 12.6, contain most recent estimates of U.S. energyrelated CO2 emissions, total and by the electric power sector.

Electric Power Annual, Table 3.9, contains historical data on CO2 emissions from all electricity 

generation (conventional power plants and combined-heat-and-power plants).

What are greenhouse gases and how much are emitted by the United States?

Last updated: August 23, 2013
<PAGE>   1

                                                                    EXHIBIT 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

     We consent to the incorporation by reference in the Prospectus constituting
part of the Registration Statements on Form S-3 (No. 333-52081, No. 333-72037
and No. 333-48384) and the Registration Statements on Form S-8 (No. 333-15947,
No. 333-62039 and No. 333-92169) of our report dated February 20, 2001, with
respect to the financial statements of Aradigm Corporation included in the
Annual Report (Form 10-K) for the year ended December 31, 2000.

                                          /s/  ERNST & YOUNG LLP

Palo Alto, California
March 29, 2001
#### Ex parte R. W. ALEXANDER (two cases).

Nos. 28188, 28189.

Court of Criminal Appeals of Texas.

April 25, 1956.

No appearance for appellant.

Leon B. Douglas, State’s Atty., Austin, for the State.

*512PER CURIAM.

This is an appeal from an order of the Criminal District Court No. 2 of Bexar County remanding appellant to the custody of the sheriff for delivery to the agent of the demanding State.

No statement of facts accompanies the record, and no bills of exception are found therein.

The proceedings being in all things regular and no errors appearing, the judgment is affirmed.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the
consolidated financial statements of Royal Acceptance Corporation and Subsidiary
as at and for the quarter ended March 31, 2000 and is qualified in its entirety
by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   MAR-31-2000
<CASH>                                              74,441
<SECURITIES>                                             0
<RECEIVABLES>                                            0
<ALLOWANCES>                                             0
<INVENTORY>                                      1,674,701
<CURRENT-ASSETS>                                 9,020,576
<PP&E>                                             193,035
<DEPRECIATION>                                      86,204
<TOTAL-ASSETS>                                  30,623,295
<CURRENT-LIABILITIES>                            7,129,758
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                             7,713
<OTHER-SE>                                       1,562,419
<TOTAL-LIABILITY-AND-EQUITY>                    30,623,295
<SALES>                                                  0
<TOTAL-REVENUES>                                 1,388,500
<CGS>                                                    0
<TOTAL-COSTS>                                      499,622
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                 430,865
<INCOME-PRETAX>                                    458,013
<INCOME-TAX>                                       178,000
<INCOME-CONTINUING>                                280,013
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                       280,013
<EPS-BASIC>                                         (0.04)
<EPS-DILUTED>                                       (0.04)


</TABLE>